ABUS Stock Forecast: Arbutus Biopharma Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$4.02
−1.23% on the day

The median 12-month analyst price target for Arbutus Biopharma Corp. is $5.32. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 82 of 100 as at 21 Nov 2026 — inside the top quartile.

Market cap
$616.2M
Ticker Nerd rank
82/ 100
Median analyst target
$5.32
Analysts covering
1
Revenue$1.0M−90.6% y/y
Operating income−$5.8M
Net income−$5.1M
Free cash flow−$6.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.7%
1M
−7.2%
YTD
−16.4%
1Y
−4.3%
From 52W high
−23.0%
From 52W low
+9.8%
$3.66
$5.22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Arbutus Biopharma Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
82/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Quality
99
Volatility
94
Value
90
Momentum
58
Accruals
53
Issuance
51
Revisions
20

Growth (99): Sales and profits are climbing, and climbing faster than before.

Revisions (20): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ABUS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABUS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$3.50$4.00$4.50$5.00$5.50Jan 26Apr 26Jul 26Oct 26ABUSHigh $5.32Median $5.32Low $5.32

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$5.32
Low
$5.32
Median
$5.32
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Nov 2025Chardan CapitalMaintainsBuy$5.00
11 Aug 2025Chardan CapitalMaintainsBuy—
28 Mar 2025Chardan CapitalMaintainsBuy—
21 Jan 2025HC Wainwright & Co.ReiteratesBuy—
20 Nov 2024Chardan CapitalMaintainsBuy—
18 Nov 2024HC Wainwright & Co.ReiteratesBuy—
7 Nov 2024Chardan CapitalMaintainsBuy—
7 Nov 2024HC Wainwright & Co.ReiteratesBuy—
6 Nov 2024Chardan CapitalMaintainsBuy$4.00 → $4.50
5 Sept 2024JefferiesMaintainsBuy—
2 Aug 2024JMP SecuritiesMaintainsMarket Outperform—
7 June 2024HC Wainwright & Co.ReiteratesBuy—
6 June 2024HC Wainwright & Co.ReiteratesBuy—
5 June 2024Chardan CapitalMaintainsBuy—
3 May 2024Chardan CapitalReiteratesBuy—
4 Apr 2024JMP SecuritiesReiteratesMarket Outperform—
1 Mar 2024Chardan CapitalReiteratesBuy—
1 Mar 2024HC Wainwright & Co.MaintainsBuy—
12 Sept 2023HC Wainwright & Co.ReiteratesBuy—
4 Aug 2023Chardan CapitalReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ABUS.

Market Radar

This page is one stock. Monday covers all of them.

ABUS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ABUS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Arbutus Biopharma Corp. returned −4.3% against +6.9% for the S&P 500, dividends included.

ABUS vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Jan 26Apr 26Jul 26Oct 26ABUSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ABUS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−0.3%
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.6×

Cheaper than 88% of US stocks

Price / sales
3.4×

Cheaper than 32% of US stocks

Price / book
9.3×

Cheaper than 8% of US stocks

EV / EBITDA
1.9×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
80.1%

Higher than 99% of US stocks

Net margin
—
Returns & dividend
Return on equity
269.6%

Higher than 99% of US stocks

Return on assets
41.6%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Arbutus Biopharma Corp. has a market value of $616.2M and an enterprise value of $282.1M.

  • Revenue in the twelve months to 30 June 2026: $181.7M. The latest quarter shrank 90.6% year on year.

  • Net income over the same four quarters: $153.1M, a 84.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$24.6M.

  • Shares outstanding: 197.6M.

  • Trailing P/E: 3.6×.

  • Arbutus Biopharma Corp. employs 19 people — $9.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ABUS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ABUSArbutus Biopharma Corp.$616.2M82
KURAKura Oncology, Inc.$613.4M53
OLMAOlema Oncology, Inc.$611.8M25
IAMIambic Therapeutics, Inc.$621.4M1
JANXJanux Therapeutics, Inc.$606.3M73
SGMTSagimet Biosciences, Inc.$638.7M35
PRMEPrime Medicine, Inc.$643.9M63

Take a look at ABUS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Arbutus Biopharma Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ABUS

What is the ABUS stock price forecast for 2026-2027?

The median 12-month analyst price target for Arbutus Biopharma Corp. is $5.32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABUS stock a buy right now?

Of the 1 analyst covering Arbutus Biopharma Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arbutus Biopharma Corp. 82 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABUS?

As at 21 Nov 2026, Arbutus Biopharma Corp. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will ABUS stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $5.32, and Ticker Nerd's factor model ranks Arbutus Biopharma Corp. 82 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABUS stock forecast for 2030?

No analyst covering Arbutus Biopharma Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABUS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.32 to $5.32 over the next 12 months.

How has ABUS stock performed over the past year?

Arbutus Biopharma Corp. returned -4.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arbutus Biopharma Corp. do?

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, with particular emphasis on chronic hepatitis B virus infection. Arbutus Biopharma Corporation is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, both designed to target different aspects of HBV biology and immune response.

Company

About Arbutus Biopharma Corp.

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, with particular emphasis on chronic hepatitis B virus infection. Arbutus Biopharma Corporation is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, both designed to target different aspects of HBV biology and immune response. The company’s work centers on advancing virology-based therapies that may contribute to improved treatment options for patients living with chronic hepatitis B. Arbutus Biopharma Corporation operates within the broader biotechnology sector, where its current programs, proprietary drug candidates, and infectious-disease focus position it as a specialized developer of novel therapeutics.

CEO Ms. Lindsay Androski J.D., M.B.A. · 19 employees · United States · https://www.arbutusbio.com